As GLP-1 weight-loss drugs rise, doctors warn eye screening cannot be ignored

As GLP-1 drugs gain ground in India, more patients are being sent for eye screening. Doctors say the shift reflects higher risks tied to diabetes, obesity and rapid blood sugar changes.

In Short

• Doctors say diabetes and obesity already raise risks of retinal disease
• Rapid blood sugar shifts can briefly worsen diabetic retinopathy after treatment
• More endocrinologists now refer patients for baseline retinal exams before therapy

The growing popularity of GLP-1 receptor agonists such as Ozempic and other semaglutide-based drugs is changing the way doctors approach diabetes and weight management in India.

Originally prescribed for type 2 diabetes, these drugs are now increasingly being used for obesity and lifestyle-related weight loss as well.

But as their use rises, eye specialists are noticing another trend: more patients are being advised to undergo regular eye screening.

According to ophthalmologists, the concern is not necessarily the medicines alone, but the health conditions linked to the people taking them.

Patients with diabetes and obesity are already at a higher risk of developing diabetic retinopathy, macular oedema, and other eye-related complications. Now, with rapid blood sugar changes triggered by GLP-1 therapies, doctors say eye monitoring is becoming even more important.

Experts also point to emerging global discussions about rare but serious eye conditions such as non-arteritic anterior ischemic optic neuropathy (NAION), a condition linked to sudden vision loss caused by reduced blood flow to the optic nerve.

Although the condition remains rare, studies have suggested a higher relative risk in patients using GLP-1 therapies, especially those already dealing with diabetes or vascular diseases.

In India, where diabetes cases continue to rise rapidly, ophthalmologists say the healthcare system must prepare for a larger screening burden and stronger coordination between endocrinologists, diabetologist, and eye specialists.

MORE HIGH-RISK PATIENTS ARE ENTERING EYE CLINICS

Dr Vineet Sehgal, Senior Consultant at Sharp Sight Eye Hospitals, said there is both a direct and indirect link between GLP-1 therapy and increased demand for eye check-ups in clinical practice.

“The link exists, and we're seeing it play out clinically in ways that deserve serious attention,” Dr. Sehgal said.

He explained that GLP-1 drugs are mostly prescribed to patients with type 2 diabetes or obesity, both of which already increase the risk of serious eye conditions. As the use of these medicines rises, the number of high-risk patients visiting clinics also increases.

Dr Sehgal added that rapid improvement in blood sugar levels, which GLP-1 drugs can trigger, may sometimes temporarily worsen diabetic retinopathy.

“That specific risk makes proactive eye screening not just advisable but essential for anyone starting this therapy,” he said.

DIABETES REMAINS THE MAIN REASON BEHIND THE SCREENING BURDEN

According to Dr Sehgal, the rising demand for eye screening cannot be blamed on drugs alone.

“The underlying conditions are the foundation. Diabetes has always driven significant demand for eye screening, and India's diabetes burden is substantial and still growing,” he explained.

However, GLP-1 therapy is importantly changing patient behaviour. More people are now entering structured treatment plans and staying connected to the healthcare system.

This means doctors are identifying eye problems earlier and referring patients for screening more consistently.

“The drugs haven't created the screening needs the diseases did. But GLP-1 adoption has brought that latent need to the surface faster than the system anticipated,” he said.

EYE SCREENING IS BECOMING PART OF TREATMENT PROTOCOLS

Doctors say eye screening is no longer being treated as a precautionary step alone.

Dr Sehgal noted that many patients starting GLP-1 therapy are now being directly referred for retinal examination and monitoring before major changes in blood sugar levels occur.

“We are actively seeing patients referred specifically because they have started GLP-1 therapy,” he said.

Some patients already have baseline diabetic eye damage that requires close observation, while others are being screened to document retinal health before treatment progresses.

According to experts, awareness among endocrinologists and diabetologists has improved significantly in recent years. More physicians are now including eye check-ups as part of routine GLP-1 treatment protocols.

“That coordination between specialities is exactly what good patient care requires,” Dr Sehgal added.

WHY PATIENTS SHOULD NOT IGNORE BLURRED VISION

Experts say not every visual symptom linked to GLP-1 therapy indicates permanent damage. Temporary blurred vision can sometimes occur because rapid blood sugar changes affect the shape of the eye’s lens.

However, doctors warn that patients should never ignore sudden vision changes, dark spots, flashes, or loss of vision, especially if they already have diabetes, high blood pressure, or vascular disease.

Routine retinal screening, they say, can help detect complications early and reduce the risk of permanent vision loss.

As semaglutide-based therapies continue expanding beyond diabetes into lifestyle and obesity treatment, specialists believe eye care systems in India will need to adapt quickly.

The focus now is shifting toward better monitoring, early detection, and stronger collaboration between physicians and ophthalmologists to ensure patients do not overlook vision health while managing weight or blood sugar.

- Ends